Supreme Court Preserves Mifepristone Telemedicine Access via Shadow Docket Stay

The U.S. Supreme Court has issued an order on its shadow docket granting a stay of a Fifth Circuit Court of Appeals decision that sought to block FDA regulations allowing the prescription of mifepristone for abortion via telemedicine. This temporary measure preserves access to the medication while the legal appeal proceeds, with the case expected to return to the Court in the future. The majority opinion did not record individual votes, but Justices Clarence Thomas and Samuel Alito filed dissenting opinions. They argued that the manufacturers failed to demonstrate irreparable harm, noting that federal law (the Comstock Act) technically prohibits mailing abortifacients and that the FDA did not intervene to defend the regulation. The dissenters suggested that any financial loss claimed by manufacturers stemmed from potentially illegal activities. The article highlights the unusual absence of federal government support for the FDA rule in this litigation, contrasting it with the strong legal standing of the pharmaceutical manufacturers who successfully argued that the lower court's reasoning was flawed and based on vacated precedents.